- Home
- EOI vs MYGN Comparison
EOI vs MYGN Comparison
Compare EOI & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOI
- MYGN
- Stock Information
- Founded
- EOI 2004
- MYGN 1991
- Country
- EOI United States
- MYGN United States
- Employees
- EOI N/A
- MYGN N/A
- Industry
- EOI Finance/Investors Services
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- EOI Finance
- MYGN Health Care
- Exchange
- EOI Nasdaq
- MYGN Nasdaq
- Market Cap
- EOI 746.6M
- MYGN 744.7M
- IPO Year
- EOI N/A
- MYGN 1995
- Fundamental
- Price
- EOI $20.09
- MYGN $4.13
- Analyst Decision
- EOI
- MYGN Hold
- Analyst Count
- EOI 0
- MYGN 16
- Target Price
- EOI N/A
- MYGN $16.40
- AVG Volume (30 Days)
- EOI 83.6K
- MYGN 3.4M
- Earning Date
- EOI 01-01-0001
- MYGN 05-06-2025
- Dividend Yield
- EOI 7.19%
- MYGN N/A
- EPS Growth
- EOI N/A
- MYGN N/A
- EPS
- EOI N/A
- MYGN N/A
- Revenue
- EOI N/A
- MYGN $831,300,000.00
- Revenue This Year
- EOI N/A
- MYGN N/A
- Revenue Next Year
- EOI N/A
- MYGN $7.21
- P/E Ratio
- EOI N/A
- MYGN N/A
- Revenue Growth
- EOI N/A
- MYGN 7.38
- 52 Week Low
- EOI $14.36
- MYGN $3.98
- 52 Week High
- EOI $18.88
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- EOI 67.80
- MYGN 25.47
- Support Level
- EOI $19.87
- MYGN $3.81
- Resistance Level
- EOI $20.16
- MYGN $4.31
- Average True Range (ATR)
- EOI 0.30
- MYGN 0.47
- MACD
- EOI 0.15
- MYGN -0.16
- Stochastic Oscillator
- EOI 96.13
- MYGN 8.00
About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.